Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer

References

• Cersosimo RJ. Lung cancer: a review. Am J Health-System Pharmacy: AJHP: Official J Am Society Health-System Pharmacists 2002; 59(7):611-42. Epub 2002/04/12; PMID:11944603
   PubMed Web of Science ®Google Scholar
• Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340:b5569. Epub 2010/01/23; PMID:20093278; https://doi.org/10.1136/bmj.b5569
   PubMed Web of Science ®Google Scholar
• Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011; 71(1):3-10; PMID:20951465; https://doi.org/10.1016/j.lungcan.2010.08.022
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Disease 2014; 5:e1257; PMID:24874729; https://doi.org/10.1038/cddis.2013.428
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31(15):1869-83; PMID:21892204; https://doi.org/10.1038/onc.2011.384
   PubMed Web of Science ®Google Scholar
• Huen MS, Chen J. The DNA damage response pathways: at the crossroad of protein modifications. Cell Res 2008; 18(1):8-16; PMID:18087291; https://doi.org/10.1038/cr.2007.109
   PubMed Web of Science ®Google Scholar
• Lai SL, Hwang J, Perng RP, Whang-Peng J. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Oncol Res 1995; 7(1):31-8; PMID:7549042
   PubMed Web of Science ®Google Scholar
• Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Therapeutics 2015; 149:124-38; PMID:25512053; https://doi.org/10.1016/j.pharmthera.2014.12.001
   PubMed Web of Science ®Google Scholar
• Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 2013; 14(4):197-210; PMID:23486281; https://doi.org/10.1038/nrm3546
   PubMed Web of Science ®Google Scholar
• Imanishi S, Umezu T, Ohtsuki K, Kobayashi C, Ohyashiki K, Ohyashiki JH. Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines. Biochem Pharmacol 2014; 89(3):361-9; PMID:24680865; https://doi.org/10.1016/j.bcp.2014.03.008
   PubMed Web of Science ®Google Scholar
• Zhang T, Shen Y, Chen Y, Hsieh JT, Kong Z. The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect. Int J Radiation Biol 2015; 91(4):368-78; PMID:25585815; https://doi.org/10.3109/09553002.2015.1001531
   PubMed Web of Science ®Google Scholar
• Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Letters 2010; 584(14):2981-9; PMID:20540941; https://doi.org/10.1016/j.febslet.2010.05.061
   PubMed Web of Science ®Google Scholar
• Song L, Coppola D, Livingston S, Cress D, Haura EB. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Therapy 2005; 4(3):267-76; PMID:15753661; https://doi.org/10.4161/cbt.4.3.1496
   PubMed Web of Science ®Google Scholar
• Jamil S, Sobouti R, Hojabrpour P, Raj M, Kast J, Duronio V. A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1. Biochem J 2005; 387(Pt 3):659-67; PMID:15554878; https://doi.org/10.1042/BJ20041596
   PubMed Web of Science ®Google Scholar
• Fujise K, Zhang D, Liu J, Yeh ET. Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem 2000; 275(50):39458-65; PMID:10978339; https://doi.org/10.1074/jbc.M006626200
   PubMed Web of Science ®Google Scholar
• Jamil S, Stoica C, Hackett TL, Duronio V. Mcl-1 localizes to sites of DNA damage and regulates DNA damage response. Cell Cycle 2010; 9(14):2843-55; PMID:20647761; https://doi.org/10.4161/cc.9.14.12354
   PubMed Web of Science ®Google Scholar
• Akgul C, Moulding DA, White MR, Edwards SW. In vivo localisation and stability of human Mcl-1 using green fluorescent protein (GFP) fusion proteins. FEBS Letters 2000; 478(1-2):72-6; PMID:10922472; https://doi.org/10.1016/S0014-5793(00)01809-3
   PubMed Web of Science ®Google Scholar
• Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 1995; 128(6):1173-84; PMID:7896880; https://doi.org/10.1083/jcb.128.6.1173
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, Jove R, Djeu JY, Loughran TP, Jr, Wei S. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol 2001; 166(12):7486-95; PMID:11390502; https://doi.org/10.4049/jimmunol.166.12.7486
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, et al. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. PloS One 2014; 9(3):e89064; PMID:24594907; https://doi.org/10.1371/journal.pone.0089064
   PubMed Web of Science ®Google Scholar
• Duan S, Tsai Y, Keng P, Chen Y, Lee SO, Chen Y. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. Oncotarget 2015; 6(29):27651-60; PMID:26313152; https://doi.org/10.18632/oncotarget.4753
   PubMed Web of Science ®Google Scholar
• Yoon JH, Ahn SG, Lee BH, Jung SH, Oh SH. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1. Biochem Pharmacol 2012; 83(6):747-57; PMID:22226932; https://doi.org/10.1016/j.bcp.2011.12.029
   PubMed Web of Science ®Google Scholar
• Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; 73(7):2271-80; PMID:23554447; https://doi.org/10.1158/0008-5472.CAN-12-3000
   PubMed Web of Science ®Google Scholar
• Lee KJ, Saha J, Sun J, Fattah KR, Wang SC, Jakob B, et al. Phosphorylation of Ku dictates DNA double-strand break (DSB) repair pathway choice in S phase. Nucleic Acids Res 2016; 44(4):1732-45; PMID:26712563; https://doi.org/10.1093/nar/gkv1499
   PubMed Web of Science ®Google Scholar
• Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, et al. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer 2015; 113(3):425-32; PMID:26180923; https://doi.org/10.1038/bjc.2015.220
   PubMed Web of Science ®Google Scholar
• Leisching G, Loos B, Botha M, Engelbrecht AM. Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance. J Translational Med 2015; 13:328; PMID:26474854; https://doi.org/10.1186/s12967-015-0689-4
   PubMed Web of Science ®Google Scholar
• Sun Y, Xu Y, Roy K, Price BD. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol 2007; 27(24):8502-9; PMID:17923702; https://doi.org/10.1128/MCB.01382-07
   PubMed Web of Science ®Google Scholar
• Eliezer Y, Argaman L, Kornowski M, Roniger M, Goldberg M. Interplay between the DNA damage proteins MDC1 and ATM in the regulation of the spindle assembly checkpoint. J Biol Chem 2014; 289(12):8182-93; PMID:24509855; https://doi.org/10.1074/jbc.M113.532739
   PubMed Web of Science ®Google Scholar
• Buscemi G, Ricci C, Zannini L, Fontanella E, Plevani P, Delia D. Bimodal regulation of p21(waf1) protein as function of DNA damage levels. Cell Cycle 2014; 13(18):2901-12; PMID:25486478; https://doi.org/10.4161/15384101.2014.946852
   PubMed Web of Science ®Google Scholar
• Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 2008; 134(2):245-53; PMID:17653574; https://doi.org/10.1007/s00432-007-0278-x
   PubMed Web of Science ®Google Scholar
• Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008; 68(18):7466-74; PMID:18794134; https://doi.org/10.1158/0008-5472.CAN-08-0763
   PubMed Web of Science ®Google Scholar
• Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, Gulappa T, Cierpicki T, Owens S, Zhang T, et al. A novel small-molecule inhibitor of Mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Therapeutics 2014; 13(3):565-75; PMID:24019208; https://doi.org/10.1158/1535-7163.MCT-12-0767
   PubMed Web of Science ®Google Scholar
• Hein AL, Ouellette MM, Yan Y. Radiation-induced signaling pathways that promote cancer cell survival (review). Int J Oncol 2014; 45(5):1813-9; PMID:25174607; https://doi.org/10.3892/ijo.2014.2614
   PubMed Web of Science ®Google Scholar
• Kim WJ, Rajasekaran B, Brown KD. MLH1- and ATM-dependent MAPK signaling is activated through c-Abl in response to the alkylator N-methyl-N′-nitro-N′-nitrosoguanidine. J Biol Chem 2007; 282(44):32021-31; PMID:17804421; https://doi.org/10.1074/jbc.M701451200
   PubMed Web of Science ®Google Scholar
• Shen C, Houghton PJ. The mTOR pathway negatively controls ATM by up-regulating miRNAs. Proc Natl Acad Sci U S A 2013; 110(29):11869-74; PMID:23818585; https://doi.org/10.1073/pnas.1220898110
   PubMed Web of Science ®Google Scholar
• Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids 2010; 2010:201367; PMID:20811617; https://doi.org/10.4061/2010/201367
   PubMedGoogle Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22(47):7265-79; PMID:14576837; https://doi.org/10.1038/sj.onc.1206933
   PubMed Web of Science ®Google Scholar
• Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kgdalton mutant adenovirus lytic infection. J Virol 1998; 72(12):9479-90; PMID:9811681
   PubMed Web of Science ®Google Scholar
• Sun SY, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, Lotan R. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 1999; 59(12):2829-33; PMID:10383141
   PubMed Web of Science ®Google Scholar
• Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108:73-112; PMID:21034966; https://doi.org/10.1016/B978-0-12-380888-2.00003-0
   PubMed Web of Science ®Google Scholar
• Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11(2):175-89; PMID:17292828; https://doi.org/10.1016/j.ccr.2006.11.024
   PubMed Web of Science ®Google Scholar
• Jamil S, Mojtabavi S, Hojabrpour P, Cheah S, Duronio V. An essential role for Mcl-1 in ATR-mediated CHK1 phosphorylation. Mol Biol Cell 2008; 19(8):3212-20; PMID:18495871; https://doi.org/10.1091/mbc.E07-11-1171
   PubMed Web of Science ®Google Scholar
• Wang B, Xie M, Li R, Owonikoko TK, Ramalingam SS, Khuri FR, Curran WJ, Wang Y, Deng X. Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis. Cell Death Differentiation 2014; 21(7):1160-9; PMID:24769731; https://doi.org/10.1038/cdd.2014.42
   PubMed Web of Science ®Google Scholar
• Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999; 5(5):1007-14; PMID:10353733
   PubMed Web of Science ®Google Scholar
• Carminati PO, Donaires FS, Marques MM, Donadi EA, Passos GA, Sakamoto-Hojo ET. Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells. Mol Biol Reports 2014; 41(1):165-77; PMID:24218165; https://doi.org/10.1007/s11033-013-2849-z
   PubMed Web of Science ®Google Scholar
• Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NM, Lau A, Newell DR, Curtin NJ. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol Cancer Therapeutics 2013; 12(6):959-67; PMID:23512991; https://doi.org/10.1158/1535-7163.MCT-12-0707
   PubMed Web of Science ®Google Scholar
• Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, Perry C, Arora A, Alsubhi N, Seedhouse C, et al. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Mol Oncol 2015; 9(1):204-17; PMID:25205036; https://doi.org/10.1016/j.molonc.2014.08.001
   PubMed Web of Science ®Google Scholar
• Cang S, Iragavarapu C, Savooji J, Song Y, Liu D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol 2015; 8:129; PMID:26589495; https://doi.org/10.1186/s13045-015-0224-3
   PubMed Web of Science ®Google Scholar
• Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PloS One 2013; 8(1):e54193; PMID:23349823; https://doi.org/10.1371/journal.pone.0054193
   PubMed Web of Science ®Google Scholar